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Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary
artery disease. It is not a valve disease but represents the valvular consequences of increased tethering forces (papillary muscles displacement
leading to a more apical position of the leaflets and their coaptation point) and reduced closing forces (reduced contractility, dyssynchrony of
the papillary muscles, intra-left ventricular dyssynchrony). Although mitral regurgitation has an unloading effect and reduces impedance, the
volume overload begets further left ventricular dilatation, increases ventricular wall stress leading to worsened performance. Ischaemic mitral
regurgitation is characteristically dynamic: its severity may vary with haemodynamic conditions. Both the severity of ischaemic mitral regurgitation
and its dynamic component worsen prognosis. There are numerous possible treatment modalities, but the management of the individual patient
remains difficult. Medical therapy ismandatory; revascularization procedures are frequently not sufficient to reducemitral regurgitation; the role of
combined surgical therapy by mitral valve repair is not yet defined in the absence of large randomized trial. Some patients are good candidates for
cardiac resynchronization therapy that may reduce the amount of regurgitation. New therapeutic targets are under investigation.
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Introduction
Appropriate systolic coaptation of the anterior and posterior
mitral leaflets depends on normal anatomy and function of the
different components of the mitral valve apparatus: annulus, leaf-
lets, chordae, papillary muscles, and the left ventricular (LV) wall.
Mitral regurgitation (MR) consists in systolic retrograde flow
from the LV to the left atrium (LA) because of the lack of adequate
coaptation of the leaflets and a pressure gradient between the two
cavities. It is important to distinguish between primary MR due to
organic disease of one or more components of the mitral valve
apparatus and secondary MR which is not a valve disease, but rep-
resents the valvular consequences of a LV disease. Secondary MR is
defined as functional MR, due to LV remodelling by idiopathic car-
diomyopathy or coronary artery disease. In the latter clinical
setting, secondary functional MR is called ischaemic MR.
There are however limitations in both terms: functional and
ischaemic. Indeed, recent studies have demonstrated evidence of
structural changes in the mitral leaflets in response to tethering
on them by LV pathological remodelling. The leaflet adaptation
includes enlargement but increased stiffness.1 On the other hand,
the term ischaemic MR does not necessarily imply the presence
of true myocardial ischaemia. It is in fact an abridgment, character-
izing a clinical situation corresponding to chronic coronary artery
disease with frequently a prior history of one or more myocardial
infarctions which induced progressive LV global or regional patho-
logical remodelling, usually in the absence of reversible ischaemia.2
Ischaemic MR is a frequent complication of chronic coronary
artery disease; it worsens prognosis.3,4 The poor prognosis
mainly depends on the severity of LV dysfunction and the specific
prognostic importance of the LV volume overload because the MR
remains controversial. Although there are numerous possible
treatment modalities, the management of this condition remains
difficult in the individual patient.
Mechanisms of ischaemic mitral
regurgitation
Reduced closing forces
Ischaemic MR results from an unbalance between increased tether-
ing forces and reduced closing forces,5 the latter including
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reduction in LV contractility, altered systolic annular contraction,
reduced synchronicity between the two papillary muscles and
global LV dyssynchrony, especially in basal segments.
Tethering forces
Inadequate closure of the mitral leaflets is the consequence of
increased tethering forces.6 The most frequent pattern corre-
sponds to a posterior infarction, usually transmural, leading to
local LV pathological remodelling and distortion contributing to
apical, posterior, and lateral displacement of the posterior papillary
muscle. The papillary muscle contributes non-extensible chordae
to both leaflets; its displacement results in a more apical position
of the leaflets and their coaptation point, and a characteristic
deformity of the anterior leaflet described as ‘seagull sign’.7 The
tethering process produces the shape of a tent between the
annular plane and the displaced leaflets. The tenting volume
relates closely to the regurgitant orifice area.8 In the case of pos-
terior infarction and regional remodelling, the tenting area is asym-
metric, predominates on the posterior leaflet close to the medial
commissure, accompanied by reduced mobility of the posterior
leaflet. In other patients, LV dilatation is more global; LV is more
spherical; both papillary muscles are displaced; the tenting area is
symmetric; the regurgitant jet is central; the contribution of
annular dilatation and flattening is more important (Figure 1).
This situation occurs in patients with previous anterior or both
anterior and posterior infarctions.
The previously held notion that ischaemic MR is caused by papil-
lary muscle dysfunction is not true. Isolated papillary muscle infarc-
tion does not produce MR and may reduce the amount of MR.9
Fibrotic elongation of papillary muscle after myocardial infarction
is an unusual lesion. In this situation, there is an association of
some degree of leaflet tethering and leaflet prolapse.10
Pathophysiology
Pathophysiology of ischaemic MR is much more complex than that
of primary MR, since myocardial damage and LV dysfunction are
the causes that precede MR. The consequences of MR depend
on the severity of regurgitation, the driving force and the acuteness
of the lesion and in turn of LA compliance. There are two relatively
rare clinical entities in which MR occurs acutely with the energy
generated by the regurgitation, transformed into potential
energy: rupture of a papillary muscle in acute myocardial infarction
and true ischaemic MR secondary to a transient active ischaemic
episode. The rupture of a papillary muscle, usually a head of the
postero-medial muscle, is a dramatic mechanical complication of
acute myocardial infarction with a high mortality rate if surgery is
not immediately performed.11 Acute ischaemic episodes linked
to a severe stenosis of the left circumflex and/or the right coronary
artery can induce ‘flash pulmonary oedema’.2
In the vast majority of patients in whom ischaemic MR is chronic
and complicates LV dysfunction and most often heart failure, LA is
Figure 1 Symmetric mitral valvular distortion and central jet of ischaemic mitral regurgitation. Upper panel: parasternal long-axis view (left)
apical four-chamber view (right). The left ventricle is dilated and spherical. Symmetric tethering of the leaflets is present, inducing large tented
area and coaptation distance. Lower panel: corresponding images showing the colour jet, originating and directed centrally.
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enlarged, more compliant and the driving force is relatively low.
The volume overload due to MR contributes to a vicious circle:
the more remodelled LV, the more severe MR which begets
further LV dilatation and thus, further MR. This cycle has important
effects on LV geometry, leading to a rather spherical LV. Although
MR reduces impedance and has an unloading effect, the LV dilata-
tion increases ventricular wall stress leading to worsened LV per-
formance.12 The upstream consequences are high LA pressure and
pulmonary arterial hypertension.
An important characteristic of ischaemic MR is its dynamic com-
ponent.13 The degree of MR is best defined by the effective regurgi-
tant orifice (ERO) area.14 The regurgitation area can change during
systole: it is less important in mid-systole when compared with early
and late systole.15 These changes are determined by dynamic
changes of transmitral pressure contributing to valve closure.16
Another aspect of the dynamic characteristics of ischaemic MR is a
possible reduction in regurgitant volume related to a reverse LV
remodelling obtained by appropriate medical treatment.17 In
patients with chronic ischaemic MR, the ERO area can also change
dynamically in the daily life, in response to changes in loading con-
ditions leading to transient episodes of increased regurgitant
volume. The dynamic characteristics of MR can be appreciated
during an exercise Doppler echocardiogram.18 The degree of MR
at rest is unrelated to exercise-induced changes in ERO area or
regurgitant volume.19 In some patients, exercise-induced changes
are low. In other patients with moderate or even severe MR at
rest, a decrease in ERO area can be observed with exercise and
usually results from contractile reserve of the LV, in particular of
the postero-basal segment and/or a reduction in intra-LV dyssyn-
chrony.20 In contrast, 30% of patients develop a severe increase
in MR and in systolic pulmonary artery pressure during exercise.
The degree of exercise-induced increase or decrease in MR
relates to changes in LV remodelling and valvular deformation and
also to changes in LV and papillary muscles synchronicity.
Diagnosis and assessment of
ischaemic mitral regurgitation
The regurgitant volume is usually much lower in ischaemic MR than
in primary MR, because of reduced LV contractility and high atrial
pressure in the former condition. Physical examination is rather
insensitive; the regurgitant murmur is frequently mild; its intensity
is unrelated to the severity of regurgitation; the auscultation may
even be normal.21 The diagnosis of ischaemic MR is usually obtained
by an imaging technique; its frequency varies according to the
method and is higher with Doppler echocardiography, when com-
pared with contrast ventriculography. Doppler echocardiography
is indeed the most useful imaging technique; several characteristics
should be obtained: quantitation of MR, LV, and mitral distortion,
functional abnormalities, and dynamic component.
Quantitation of ischaemic mitral
regurgitation
Quantitation of MR is crucial. The semi-quantitative evaluation of
regurgitant jet area should be abandoned.22 This measurement is
poorly reproducible and depends on numerous factors. The vena
contracta width is more accurate.23,24 The quantitative methods
include the Doppler volumetric method (the regurgitant volume
is calculated as the difference between mitral and aortic stroke
volumes).25 The flow-convergence method is the most practical
and permits the measurement of ERO area and regurgitant
volume.26 There are several limitations of the proximal isovelocity
surface area (PISA) approach.27 First, the PISA radius changes
during systole is larger in early and late systole, and smaller in mid-
systole when the LV pressure is maximal.16 Ideally, the PISA radius
should not be measured at only one time point, but averaged
through systole. Second, for an accurate measurement, the flow
convergence should be hemispheric. Although the most appropri-
ate aliasing velocity can be adjusted off-line on a dedicated work-
station, the flow convergence—a three-dimensional structure—is
frequently hemielliptic, implying an underestimated calculation of
ERO and regurgitant volume.28,29 Third, several jets may be
present; the addition of several flow-convergence regions has
not been validated.
Thus, practically, the most reliable calculation of regurgitant
volume and ERO area, although time-consuming, is the averaging
of the quantitative Doppler and the PISA methods. Severe ischae-
mic MR has been defined as . 30 mL regurgitant volume and .
20 mm2 ERO22,30 although this definition has not had universal
acceptance.
Mitral valve distortion
Several measurements should be obtained: leaflet length, tenting
area, apical displacement of the coaptation point, distance
between the posterior papillary muscle head and the intervalvular
fibrosa, lateral and posterior displacement of the papillary muscles,
leaflet angles (Figure 2). It is important to determine, usually from
the direction of the regurgitant jet whether the valvular distortion
is asymmetric (posterior jet) or symmetric (central jet) (Figure 3).
Three-dimensional echocardiography permits the measurement of
tenting volume and a better definition of annular geometry and
dynamics.
Left ventricular function and pathological
remodelling
Left ventricular abnormalities should be defined and quantified: LV
end-diastolic and end-systolic volumes, assessment of sphericity,
regional abnormalities, including location of necrotic segments,
myocardial thickness of akinetic regions, and LV ejection fraction.
This parameter if highly dependent of loading conditions and,
when MR is significant, is overestimated as it represents the
addition of forward LV ejection fraction and the regurgitant
fraction.
The mitral closing force can be estimated by the measurement
of intra LV dyssynchrony and/on the non-invasive calculation of
LV maximal dP/dt, obtainable by the continuous-wave Doppler
method, as the time interval between 1 and 3 ms21 velocities of
the regurgitation. Left ventricular dP/dt is calculated by the simpli-
fied Bernouilli equation as 32 mmHg/time interval in second.
Thirty-two millimetres of mercury represents the difference
between 36 mmHg (velocity of 3 ms21) and 4 mmHg (velocity of
1 ms21) (Figure 4). It is important to recognize that dP/dt is an
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isovolumetric measure of LV function. Because no true isovolumic
phase exists in MR (ejection occurs into the LA well before the
aortic valve opens) dP/dt not only varies directly with contractility
but also inversely with the severity of the MR present.
Dynamic component
Ischaemic MR is characteristically dynamic.2 The dynamic com-
ponent can be assessed and quantified by exercise echocardiogra-
phy. If the exercise test is performed on a dedicated table, in
Figure 3 Left: severe asymmetric mitral regurgitation: the proximal isovelocity surface area radius is 12 mm with aliasing velocity of
33 cm s21. Right: continuous-wave Doppler recording. The effective regurgitant orifice is 60 mm2 and the regurgitant volume is 76 mL.
Figure 2 Echo morphologic parameters that are measured in ischaemic mitral regurgitation. (A) Global left ventricular remodelling [diameter,
left ventricle volumes, sphericity index (sphericity index ¼L/1; L, major axis; 1, minor axis)]. (B) Local left ventricular remodelling (1, apical
displacement of the posteromedial papillary muscle; 2, second order cords; 3, interpapillary muscle distance). (C) Mitral valve deformation
(1, systolic tenting area; 2, coaptation distance; 3, posterolateral angle). Reproduced with permission from Lancellotti et al.22
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semi-supine position, numerous parameters can be obtained during
exercise and not only during the recovery period.18 Effective regur-
gitant orifice area and regurgitant volume can be obtained with an
excellent reproducibility. In the presence of at least a trivial tricuspid
regurgitation, continuous-wave Doppler recording of its velocity
permits the measurement of transtricuspid pressure gradient and
an estimation of systolic pulmonary artery pressure.31
Exercise-induced changes in the ERO area, the systolic pulmonary
artery pressure and the LV ejection fraction can be obtained.
Other interesting measurements can be obtained during exercise:
the tenting area (its changes correlate well with changes in the
severity of MR) and LV dyssynchrony (exercise-induced increase
of dyssynchrony correlates with increased severity of MR and
reduction in stroke volume during exercise).19,32
Outcomes
The presence of ischaemic MR is associated with increased mor-
bidity and mortality. In acute myocardial infarction, MR may pre-
exist or more frequently, results from the acute event through
regional LV dilation and loss of contraction. When compared
with patients without MR, the patients with acute infarction and
MR are older, more frequently female, have more frequently a
history of previous myocardial infarction and a more severe coron-
ary artery disease. The size of dyssynergy is usually larger. Many
studies have shown that ischaemic MR is an independent predictor
of cardiovascular death.3,4,33–35 The relative risk varies from 1.48
to 7.5. The worse long-term prognosis is also observed in patients
with a first non-ST segment elevation acute coronary syndrome.36
Among one-month survivors of myocardial infarction, a commu-
nity study has also confirmed the prognostic importance of ischae-
mic MR: its presence is associated with a three-fold increase in the
risk of heart failure and a 1.6-fold increased risk of death at 5-year
follow-up, independent of LV ejection fraction, Killip class, age and
gender.3 The increased mortality risk relates to the quantified
degree of MR.30 Survival curves are strikingly different between
patients with no ischaemic MR, moderate MR (ERO area ,
20 mm2) or severe MR (ERO area . 20 mm
2
). The prognosis is
worse in the latter subgroup. However, the severity of ischaemic
MR tends to follow the severity of the LV dysfunction causing
the MR; the worse the MR, the worse the LV function. Currently
there are no studies of outcome using sophisticated measures of
LV function to determine whether ischaemic MR is a predictor
of outcome independent of the amount of LV dysfunction
present. Supporting this concept is the lack of evidence that cor-
rection of ischaemic MR prolongs life which would be expected
to occur if MR were an independent risk factor for death
beyond the LV dysfunction present.
The dynamic component of ischaemic MR has also prognostic
implications. At 3-year follow-up, there is a five-fold increase in
the relative risk of death in patients with an exercise-induced
increase of ≥13 mm2 of the ERO area.37 The multivariate analysis
shows that severe MR at rest (≥20 mm2) is also an independent
predictor of death. The severity of MR at rest has, in contrast,
no independent value to predict cardiovascular morbidity and in
particular hospitalization for cardiac decompensation. The
dynamic component is the best predictor of such complications
(Figure 5). The deleterious effect of ischaemic MR is probably
Figure 4 The assessment of mitral valve closing force. Left: estimation of left ventricular dP/dt. The time interval between 1 and 3 ms21 vel-
ocity of the regurgitation is 71 ms. The estimation of left ventricular dP/dt is 32/71 ¼ 451 mmHg s21. Right: important left ventricular dyssyn-
chrony. The time intervals between peak velocities of the basal left ventricular segments vary from 110 to 170 ms.
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related to different factors. The frequent acute increase in regurgi-
tant volume raises the volume overload and contributes to further
LV dilatation. In addition, frequent acute increases in ventricular
wall stress are associated with rapid QRS widening and in turn,
worsening in LV dyssynchrony.38 The prognostic importance of
dynamic ischaemic MR is not necessarily applicable to functional
MR due to non-ischaemic dilated cardiomyopathy or in patients
with mild MR at rest.39
In patients with LV systolic dysfunction, acute pulmonary
oedema has been shown to be associated with dynamic changes
in ischaemic MR and the resulting increase in pulmonary vascular
pressure.40 When mild or moderate ERO area and regurgitant
volume suddenly increase, the acute raise in LA pressure can be
transmitted back to the pulmonary circulation, generating pulmon-
ary oedema. Exertional dyspnoea is also related with a large
exercise-induced increase in MR and in systolic pulmonary arterial
pressure41 (Figure 6).
In 20% of patients, an improvement in the severity of ischaemic
MR is observed during exercise. These patients have a better long-
term prognosis.37 Such a reduction is most frequently observed in
patients with contractile reserve, especially of the posterior wall,
resulting in a temporary reduced distortion of the mitral valve.19
The conundrum of treatment
Although the pathophysiology and the clinical consequences of
ischaemic MR are well defined, this condition is still in search of
its best treatment.42 A potential explanation of the controversy
in the management of ischaemic MR is that it is not known
whether the MR is simply a marker of LV dilatation and dysfunction
or whether MR is directly the cause of the poor prognosis as noted
above. In brief, medical therapy is mandatory in all patients. Some
patients are good candidates for cardiac resynchronization therapy
(CRT) that may reduce the amount of MR. Percutaneous coronary
intervention is usually not sufficient to reduce MR. In patients sub-
mitted to coronary artery bypass grafting (CABG), the role of
combined therapy by mitral valve repair is not yet well defined.
New therapeutic targets are currently under investigation but
their role has yet to be validated.
The management of the individual patient should be selected
according to a careful integration of clinical data and the results
of cardiac imaging. The clinical parameters include age, functional
NYHA class, episodes of acute heart failure, and comorbidities,
such as diabetes and renal dysfunction. Parameters obtained with
imaging techniques, especially Doppler echocardiography, include
the severity of MR at rest, the dynamic component, the importance
of LV pathological remodelling, the presence and extent of con-
tractile reserve, myocardial viability and inducible ischaemia, the
presence and extent of LV dyssynchrony, and the relative contri-
bution of tethering and mitral valve closing forces.43
Medical therapy
Medical treatment should be given in line with the guidelines in the
management of heart failure.44 Medical treatment includes an
angiotensin-converting enzyme (ACE) inhibitor (or an angiotensin
receptor blocker if the ACE-inhibitor is not well tolerated). A
beta-blocker should be prescribed and titrated appropriately,
using carvedilol, bisoprolol, or metoprolol. An aldosterone antag-
onist is given in the presence of heart failure. A diuretic can be
added in the presence of fluid overload. Several of these agents
can progressively produce LV reverse remodelling and in turn
reduce the tethering force and the severity of ischaemic MR.45 In
patients with a large dynamic component, episodes of acute dys-
pnoea can be treated by sublingual nitrate.
Cardiac resynchronization therapy
The candidates for CRT have usually significant ischaemic MR.
However, ischaemic MR per se is not an indication for biventricular
pacing. This modality is indicated in patients in functional class III–
IV despite optimal medical treatment, reduced LV ejection fraction
and QRS duration .120 ms.46 Cardiac resynchronization therapy
produces an immediate reduction in MR through increased closing
force, usually due to resynchronization of papillary muscles.47,48
In responders, a further reduction in the severity of MR is observed
after several weeks or months, through a reduction in tethering
Figure 5 (A) Proportion of patients without admission for heart failure and (B) without major adverse cardiac events, according to
exercise-induced differences in effective regurgitant orifice area of mitral regurgitation. Reproduced with permission from Lancellotti et al.37
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forces, in relation with LV reverse remodelling. Cardiac resynchro-
nization therapy may also result in an improved contraction of the
mitral annulus. Although the severity of MR is usually reduced,
residual MR persists in most cases. In several studies evaluating
the effects of withdrawal of CRT, the immediate dyssynchroniza-
tion of the papillary muscles leads to immediate recurrence of
MR.49–51
Cardiac resynchronization therapy can also reduce dynamic
MR.52 The time course of CRT on dynamic MR has been deter-
mined.53 One week after implantation, CRT induced a decrease
in LV dyssynchrony and in MR severity but not a reduction in
the dynamic component of MR. Three months after implantation,
the magnitude of exercise-induced MR was significantly attenuated
in parallel to reverse LV remodelling and resulted in improved car-
diopulmonary performance.
Percutaneous coronary intervention
In the minority of patients in whom MR is directly related to indu-
cible myocardial ischaemia, percutaneous coronary intervention
may lead to a reduction in MR at rest and exercise.
Surgical treatment
In contrast to primary MR which can usually be eliminated after
surgical valve repair, surgical treatment of ischaemic MR can only
reduce its severity. Persistence and recurrence of MR and the
absence of evidence that surgery prolongs life may explain the
current controversies. The indication of surgical correction of
MR is usually discussed in patients who are candidates to bypass
surgery. Coronary artery bypass grafting alone usually does not
correct MR.54 The persistence of even mild to moderate residual
MR has been shown to be associated with increased mortality
risk.55 Although the use of a prosthetic undersized (preferably
two-sizes) ring can be performed with a low operative mortality56
and can lead to a reduction in LV volume and even a small increase
in LV ejection fraction,57 the long-term benefit remains question-
able.58,59 Several studies using propensity-matched groups analysis
indicate that long-term functional status or survival is not improved
by combined surgery.58,60,61 A recent randomized trial showed
that the addition of mitral valve repair to CABG was associated
with improvement of the New York Heart Association functional
class, percentage of LV ejection fraction, and with decrease in LV
diameter, pulmonary artery presence and LA size.62 The study
was not powered to analyse the effect on survival. In summary,
some valves probably should be fixed in certain patients who
still remain difficult to identify.63
The ESC guidelines recommend that patients with severe
ischaemic MR (ERO area ≥20 mm2) submitted to CABG
should be treated by combined surgery (class I, level of evidence
Figure 6 Large exercise-induced increase in ischaemic mitral regurgitation. Upper panel showing at rest, from left to right: vena contracta
width (5 mm), the proximal isovelocity surface area radius, Doppler continuous-wave recording of regurgitant jet and functional tricuspid regur-
gitation. Effective regurgitant orifice ¼22 mm2; Regurgitant volume ¼40 mL; Transtricuspid pressure gradient ¼36 mmHg. Lower panel
showed corresponding images obtained during exercise. Vena contracta width 7 mm; Effective regurgitant orifice ¼38 mm2 (exercise-
induced increase of 16 mm2); Regurgitant volume ¼69 mL, Transtricuspid pressure gradient ¼77 mmHg.
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C).64 The indications of mitral valve repair in symptomatic
patients with severe MR who cannot be revascularized are
more questionable. Surgery may be considered (class IIb, level
of evidence C).64 Patients with mild or trivial MR should not
be operated. The most controversial issue is the role of com-
bined therapy in patients with moderate MR (ERO .10 mm2
but ,20 mm2). In the absence of clear evidence, the manage-
ment could be individualized. The decision should integrate the
presence of myocardial viability, inducible ischaemia and the
dynamic component of MR. It is important to predict whether
revascularization will be associated with sufficient functional
recovery, especially at the level of the posterior basal wall and
in turn, will decrease tethering forces, increase mitral valve
closing force and thus, correct or at least sufficiently reduce
MR. Regional contractile reserve or biphasic response during
stress can help in such decisions. These patients usually have
exercise-induced reduction in MR or no significant changes. Intui-
tively, patients with dynamic increase in MR during exercise
(exercise-induced increase in ERO area ≥13 mm2) could be sub-
mitted to combined surgery. However, such an approach has not
yet been validated. Intra-operative transoesophageal echocardio-
graphy is frequently performed for selecting the candidates
who should be submitted to combined surgery. However, the
severity of MR is always underestimated because of the loading
conditions associated with general anaesthesia. Several groups
use a preload and/or afterload challenge: rapid fluid adminis-
tration until the capillary wedge pressure is at least 15 mmHg
and if necessary, intravenous bolus of phenylephrine to increase
afterload and obtain during echocardiographic examination systo-
lic blood pressure at or above the preoperative level.65
The specific contribution of annular dilatation in the develop-
ment of ischaemic MR is usually mild. It is not surprising that
even undersized ring annuloplasty fails to eliminate the subvalvular
component of leaflet tethering. Undersized ring reduces the
anterior–posterior annular dimension, frequently associated with
a decrease in LV dimension at early follow-up but the incidence
of persistence or recurrence of MR is relatively high.66 Several
factors can explain this treatment failure: persistence or even
increase in tethering of both leaflets, progressive LV remodelling
and progression of coronary artery disease.67–69 The two latter
causes can explain the absence of clinical long-term benefit. In
addition, a restrictive mitral valve annuloplasty may create a func-
tional mitral stenosis, associated with a higher systolic pulmonary
arterial pressure and a worse functional capacity.70
To prevent such disappointment, it is useful to identify pre-
operatively the patients at risk of persistence or recurrence and/
or use additional subvalvular repair techniques.
Echocardiographic predictors of unsuccessful mitral repair by
annuloplasty alone have been identified: systolic sphericity index,
end-systolic volume, wall motion score index, severe MR, large sys-
tolic tenting area (.2.5 cm2), large distance between the coapta-
tion point and the mitral annulus plane (.1 cm), large angle
(≥458) of the posterior leaflet, very enlarged LV or the presence
of several regurgitant jets.66,68,71
Several surgical modalities have been performed in patients and
other approaches have been investigated in experimental studies.
These adjunctive techniques may consist in internal direct
repositioning of the displaced papillary muscle, infarct plication
using plaquating sutures, external repositioning of the displaced
papillary muscle using an epicardial patch containing an inflatable
balloon, or chordal cutting,7 although this latter technique, useful
in the experimental setting has not yet shown clinical benefit.
Moreover, a retrospective analysis of outcome was obtained in
patients with ischaemic MR who underwent mitral valve repair
or mitral valve replacement. After adjusting for risk factors and
propensity score, the type of procedure was not an independent
predictor of operative and overall mortality.72 However, a recent
meta-analysis indicates that mitral valve repair for ischaemic MR
is associated with better short-term and long-term survival com-
pared with mitral valve replacement.73
Percutaneous techniques
Several percutaneous modalities are currently investigated. Percu-
taneous edge-to-edge Alfieri procedure has been proposed to
reduce organic and also ischaemic MR, through the apposition of
the centre of the two mitral leaflets, producing a double orifice.74
Several interventions take advantage of the close proximity of
the posterior mitral annulus to the coronary sinus. Several
devices can be inserted into the coronary sinus to remodel the
posterior portion of the annulus, modify its shape and push the
posterior leaflet forward, restoring mitral competence or at
least, reducing the severity of MR75,76 (Figure 7). Although most
devices can be inserted successfully and can reduce MR in the
short term, maintenance of these effects over time and long-term
clinical benefit remains to be established.
Future therapeutic targets
Autologous myoblast transplantation in the infarcted area has been
used in an experimental model, showing the potential of decreas-
ing ischaemic MR by a localized LV reverse remodelling.77
The recently observed mitral leaflet adaptation to LV remodel-
ling could potentially be in the future a therapeutic target when the
mechanisms that underly leaflet adaptation will be completely
understood and if they can be potentially modified.1
Conclusion
Chronic ischaemic MR is a frequent and important complication
after myocardial infarction and is associated with an increased
risk of heart failure and cardiac mortality. It is the consequence
of damaged pathologically remodelled LV inducing apical and pos-
terior papillary muscle displacement and tethered leaflets. Mitral
valve tenting is accompanied by an enlarged and flattened
annulus and decreased mitral valve closing forces. The specific
role of MR in the poor prognosis of patients with this condition
remains controversial but is probable as the most severe the
MR, the worse the outcome, independently of age and ejection
fraction. Ischaemic MR is characteristically dynamic and can
change substantially with changes in loading conditions, in mitral
valve distortion and in LV dyssynchrony.
Although medical treatment is mandatory, is it usually insuffi-
cient. Cardiac resynchronization therapy may help the good candi-
dates for this therapy. Surgical correction of MR can be performed
with a low surgical mortality; however, it provides significant but
Ischaemic mitral regurgitation 3003









Figure 7 (A) Progressive dilatation of mitral annulus in a 5-year period with concomitant decrease in the posterolateral angle (in degrees). (B)
Severe ischaemic mitral regurgition: mitral annular diameter ¼51 mm; tenting area ¼3.9 cm2; effective regurgitant orifice ¼50 mm2; regurgitant
volume ¼79 mL. (C) Early results of percutaneous remodelling of mitral annulus by straightening rods within a catheter positioned in the cor-
onary sinus. Mitral annular diameter and tenting area decreased to 41 mm and 3.6 cm2, respectively. The severity of mitral regurgitation is
reduced: effective regurgitant orifice ¼20 mm2; regurgitant volume ¼42 mL.
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usually temporary reduction in MR without changing significantly
the long-term prognosis. The future role of new adjunctive surgical
techniques and of percutaneous interventions is not yet deter-
mined. Importantly, clinical randomized trials are mandatory to
provide guidelines with improved level of evidence.
Conflict of interest: none declared.
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